Tirzepatide 30mg

$499.99

Tirzepatide 30mg is a dual-action peptide that activates both GLP-1 and GIP receptors, making it one of the most powerful tools in clinical metabolic research. Designed for subcutaneous injection, this multi-use vial supports sustained weight loss, insulin regulation, and blood sugar control. Researchers use tirzepatide for its advanced performance in combating obesity, insulin resistance, and type 2 diabetes.

🔑 Key Benefits:

  • Targets two metabolic pathways (GIP + GLP-1) for superior fat loss and insulin optimization.

  • Reduces body weight by up to 22% in long-term trials.

  • Improves glycemic control with significant A1C reductions.

  • Pharmaceutical-grade multi-use vial for precision dosing.

Description

🧬 What Is Tirzepatide?

Tirzepatide is a novel investigational peptide that functions as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is the first-in-class medication of its kind, studied for its superior ability to reduce weight and improve insulin response compared to GLP-1 agonists alone (like semaglutide).

By mimicking both incretin hormones, tirzepatide boosts postprandial insulin release, delays gastric emptying, and decreases appetite — creating a powerful effect on energy intake and glucose metabolism.

Researchers value this compound for its multi-pathway metabolic impact, long half-life, and weekly injection protocol that aligns with real-world compliance studies.


🔬 Compound Details

Compound Dosage Targets Primary Use
Tirzepatide 30 mg GIP and GLP-1 receptors Obesity, insulin resistance, glycemic study

Tirzepatide’s ability to target two incretin pathways gives it synergistic effects on reducing food intake, enhancing insulin sensitivity, and suppressing glucagon.


🧠 Mechanism of Action

Tirzepatide binds to both GIP and GLP-1 receptors to:

  • Enhance insulin secretion in response to nutrient intake.

  • Reduce hepatic glucose output by suppressing glucagon.

  • Slow gastric emptying to prolong satiety.

  • Reduce reward-based eating behaviors.

  • Improve lipid profiles and insulin sensitivity.

This dual-targeting mechanism leads to greater weight loss and metabolic correction compared to single-pathway peptides.


Clinical Outcomes

Tirzepatide has demonstrated superior results in several large-scale clinical studies. Key findings include:

Study Result Outcome
Average weight loss Up to 22.5% body weight (SURMOUNT-1 study)
HbA1c reduction Up to 2.4 percentage points
Fat mass reduction Measurable reduction in visceral fat
Insulin resistance improvement Increased insulin sensitivity
Compliance 1x/week dosing improves subject adherence

Use Cases in Research

  • Obesity intervention studies

  • Appetite suppression and satiety trials

  • Type 2 diabetes research

  • Insulin resistance modulation

  • Long-term metabolic optimization protocols


Administration & Storage Instructions

For Research Use Only – Not For Human Use

  1. Reconstitute with sterile bacteriostatic water (per vial volume specs).

  2. Draw accurate dosage using sterile insulin syringe.

  3. Administer subcutaneously in the abdomen or thigh weekly.

  4. Store between 2°C – 8°C (36°F – 46°F) after reconstitution.

  5. Discard within 28 days of first use.


Advantages Over GLP-1 Agonists Alone

  • Activates two incretin pathways, not just GLP-1

  • Greater fat loss efficiency (superior to semaglutide in head-to-head trials)

  • Improved metabolic profile: better glucose, lipids, and blood pressure

  • Reduced GI side effects in some cohorts

  • Sustained results over 72-week trials with weekly use


Frequently Asked Questions

1. What is Tirzepatide 30mg used for in research?

Tirzepatide is used to study fat loss, insulin resistance, and blood sugar regulation via dual incretin pathway activation.

2. Can I buy tirzepatide online for research?

Yes, tirzepatide peptide is available for sale from certified research suppliers. Survival Supplements offers pharmaceutical-grade vials for clinical research.

3. How is tirzepatide different from semaglutide?

Unlike semaglutide (GLP-1 only), tirzepatide activates both GLP-1 and GIP receptors, resulting in superior fat loss and A1C reduction.

4. What’s the mechanism behind tirzepatide’s weight loss?

Tirzepatide reduces appetite, slows digestion, and enhances insulin function, all of which promote energy deficit and fat oxidation.

5. What is the proper tirzepatide dosage for studies?

Typical weekly doses range between 2.5mg and 15mg, depending on protocol progression. This 30mg vial supports multi-week dosing.

6. Is this a subcutaneous injection?

Yes. Tirzepatide is injected subcutaneously, similar to other peptide hormones like GLP-1 agonists.

7. How often should tirzepatide be administered?

Weekly administration is standard in most research protocols due to the compound’s long biological half-life.

8. Does tirzepatide suppress appetite?

Yes. It activates satiety centers in the hypothalamus, resulting in reduced food intake and improved eating control.

9. Can I use tirzepatide for metabolic research?

Absolutely. Tirzepatide is clinically proven to impact metabolic markers, including insulin sensitivity, lipid metabolism, and body composition.

10. Is tirzepatide available in single-use or multi-use vials?

This 30mg format is a multi-use vial, allowing flexibility in dose adjustments and longer research cycles.

11. Where to buy tirzepatide peptide?

You can buy tirzepatide online for research use from licensed vendors like Survival Supplements.

12. What are the expected outcomes in obese models?

In trials, tirzepatide induced over 20% body weight loss when administered consistently over 72 weeks.

13. What makes tirzepatide a “dual agonist”?

It mimics both GIP and GLP-1, offering dual action for enhanced glucose regulation and fat loss.

14. Is this peptide pharmaceutical-grade?

Yes. The product is pharmaceutical-grade, sterile, and manufactured for clinical or laboratory research environments.

15. How long does one vial last in weekly research dosing?

A 30mg vial may last between 3 to 6 weeks, depending on the starting dose (e.g., 2.5mg escalated to 15mg weekly).